iTeos Therapeutics, Inc. (NASDAQ:ITOS) Shares Sold by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lessened its stake in iTeos Therapeutics, Inc. (NASDAQ:ITOS) by 4.0% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 56,507 shares of the company’s stock after selling 2,333 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.15% of iTeos Therapeutics worth $577,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. nVerses Capital LLC raised its position in iTeos Therapeutics by 212.5% during the third quarter. nVerses Capital LLC now owns 2,500 shares of the company’s stock valued at $26,000 after acquiring an additional 1,700 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its stake in shares of iTeos Therapeutics by 60.4% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,024 shares of the company’s stock valued at $72,000 after purchasing an additional 2,646 shares during the period. Quest Partners LLC boosted its holdings in iTeos Therapeutics by 914.7% during the third quarter. Quest Partners LLC now owns 11,020 shares of the company’s stock worth $113,000 after buying an additional 9,934 shares in the last quarter. The Manufacturers Life Insurance Company grew its position in iTeos Therapeutics by 6.6% during the second quarter. The Manufacturers Life Insurance Company now owns 11,071 shares of the company’s stock valued at $164,000 after buying an additional 690 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in iTeos Therapeutics by 35.9% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,998 shares of the company’s stock valued at $178,000 after buying an additional 3,172 shares in the last quarter. Hedge funds and other institutional investors own 97.16% of the company’s stock.

Insider Buying and Selling at iTeos Therapeutics

In related news, CFO Matthew Gall bought 5,000 shares of the stock in a transaction dated Tuesday, November 19th. The shares were acquired at an average cost of $7.73 per share, for a total transaction of $38,650.00. Following the acquisition, the chief financial officer now directly owns 65,429 shares in the company, valued at approximately $505,766.17. This trade represents a 8.27 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 12.50% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on ITOS shares. HC Wainwright reissued a “buy” rating and set a $21.00 target price on shares of iTeos Therapeutics in a research note on Friday, December 13th. Wedbush reiterated an “outperform” rating and set a $25.00 price target on shares of iTeos Therapeutics in a research report on Thursday, December 12th. Finally, Wells Fargo & Company dropped their price objective on iTeos Therapeutics from $31.00 to $19.00 and set an “overweight” rating on the stock in a report on Thursday.

iTeos Therapeutics Stock Up 2.8 %

ITOS opened at $7.42 on Friday. The company has a market cap of $271.08 million, a PE ratio of -2.36 and a beta of 1.37. iTeos Therapeutics, Inc. has a twelve month low of $7.09 and a twelve month high of $18.75. The company has a 50-day moving average price of $8.54 and a 200 day moving average price of $12.65.

iTeos Therapeutics (NASDAQ:ITOS) last released its earnings results on Tuesday, November 12th. The company reported ($1.05) earnings per share for the quarter, beating the consensus estimate of ($1.18) by $0.13. As a group, sell-side analysts expect that iTeos Therapeutics, Inc. will post -3.46 earnings per share for the current year.

iTeos Therapeutics Company Profile

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.